Is CVS Health Stock Undervalued?
CVS Health (NYSE:CVS) share price declined by over 23% over…
Buy
55
KVUE Quote, Financials, Valuation and Earnings
Last price:
$21.29
Seasonality move
:
-4.21%
Day range:
$21.28 - $21.63
52-week range:
$17.67 - $24.46
Dividend yield:
3.81%
P/E ratio:
38.71x
P/S ratio:
2.65x
P/B ratio:
3.83x
Volume:
16.3M
Avg. volume:
11.6M
1-year change:
2.55%
Market cap:
$40.8B
Revenue:
$15.4B
EPS (TTM):
$0.55
Analysts' Opinion
-
Consensus RatingKenvue has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.44, Kenvue has an estimated upside of 14.78% from its current price of $21.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 1.36% downside risk from its current price of $21.29.
Fair Value
-
According to the consensus of 14 analysts, Kenvue has 14.78% upside to fair value with a price target of $24.44 per share.
KVUE vs. S&P 500
-
Over the past 5 trading days, Kenvue has overperformed the S&P 500 by 3.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kenvue does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kenvue revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Kenvue reported revenues of $3.9B.
Earnings Growth
-
Kenvue has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kenvue reported earnings per share of $0.20.
Enterprise value:
48.5B
EV / Invested capital:
--
Price / LTM sales:
2.65x
EV / EBIT:
25.33x
EV / Revenue:
3.13x
PEG ratio (5yr expected):
--
EV / Free cash flow:
34.59x
Price / Operating cash flow:
29.19x
Enterprise value / EBITDA:
18.94x
Gross Profit (TTM):
$8.9B
Return On Assets:
3.92%
Net Income Margin (TTM):
6.88%
Return On Equity:
9.94%
Return On Invested Capital:
5.56%
Operating Margin:
18.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $14.9B | $15.5B | $15.5B | $3.9B | $3.9B | |
| Gross Profit | $8.2B | $8.6B | $8.9B | $2.3B | $2.3B | |
| Operating Income | $2.7B | $2.6B | $2.5B | $710M | $703M | |
| EBITDA | $3.2B | $3.1B | $2.6B | $838M | $855M | |
| Diluted EPS | $1.15 | $0.90 | $0.55 | $0.23 | $0.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $5.5B | $5.9B | $5.9B | |
| Total Assets | -- | -- | $26B | $27.1B | $26.9B | |
| Current Liabilities | -- | -- | $3.9B | $5.2B | $5.9B | |
| Total Liabilities | -- | -- | $7.1B | $16.2B | $16.3B | |
| Total Equity | -- | -- | $18.9B | $10.9B | $10.6B | |
| Total Debt | -- | -- | -- | $8.2B | $8.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $2.9B | $1.9B | $674M | $249M | |
| Cash From Investing | -- | -$390M | -$558M | -$105M | -$56M | |
| Cash From Financing | -- | -$2.2B | -$1.4B | -$726M | -$162M | |
| Free Cash Flow | -- | $2.5B | $1.4B | $560M | $190M | |
KVUE
Sector
Market Cap
$40.8B
$296.6M
Price % of 52-Week High
87.04%
72.58%
Dividend Yield
3.81%
0%
Shareholder Yield
3.62%
2.67%
1-Year Price Total Return
2.55%
-13.86%
Beta (5-Year)
--
0.494
Dividend yield:
3.81%
Annualized payout:
$0.00
Payout ratio:
144.93%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$21.18
200-day SMA
Buy
Level
$20.99
Bollinger Bands (100)
Sell
Level
21.43 - 23.43
Chaikin Money Flow
Sell
Level
-268.2M
20-day SMA
Buy
Level
$21.10
Relative Strength Index (RSI14)
Sell
Level
48.01
ADX Line
Buy
Level
26.1
Williams %R
Neutral
Level
-37.3541
50-day SMA
Sell
Level
$22.10
MACD (12, 26)
Sell
Level
-0.15
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-155.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3933)
Buy
CA Score
(Annual)
Level (0.4703)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.3869)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
Stock Forecast FAQ
In the current month, KVUE has received 3 Buy ratings 11 Hold ratings, and 0 Sell ratings. The KVUE average analyst price target in the past 3 months is $24.44.
-
Where Will Kenvue Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kenvue share price will rise to $24.44 per share over the next 12 months.
-
What Do Analysts Say About Kenvue?
Analysts are divided on their view about Kenvue share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kenvue is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Kenvue's Price Target?
The price target for Kenvue over the next 1-year time period is forecast to be $24.44 according to 14 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is KVUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kenvue is a Hold. 11 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of KVUE?
You can purchase shares of Kenvue via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kenvue shares.
-
What Is The Kenvue Share Price Today?
Kenvue was last trading at $21.29 per share. This represents the most recent stock quote for Kenvue. Yesterday, Kenvue closed at $21.29 per share.
-
How To Buy Kenvue Stock Online?
In order to purchase Kenvue stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Can RTX Stock Go?
Needless to say, the geopolitical landscape has heated up significantly…
What Is Recency Bias in Investing?
Recency bias is a cognitive error that happens when people…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Sell
38
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 101x
Alerts
Buy
54
DECK alert for Feb 1
Deckers Outdoor [DECK] is down 20.35% over the past day.
Sell
49
EXOD alert for Feb 1
Exodus Movement [EXOD] is down 18.88% over the past day.
Buy
69
HZO alert for Feb 1
MarineMax [HZO] is down 0.13% over the past day.
